and fast acting; however, long-term exposure to corticosteroids leads to drug dependency and/or resistance 2) .Several randomized, placebo-controlled studies have demonstrated that the biological drug infliximab (Remicade: Centocor Ortho Biotech, Malvern, PA, USA), a monoclonal immunoglobulin G1 chimeric antibody directed against tumor necrosis factor-α , is highly effective in improving the clinical course in patients with CD [3] [4] [5] [6] [7] [8] [9] . Since receiving FDA approval for pediatric use in May 2006, infliximab has been widely used in pediatric patients with CD 10) . The efficacy of infliximab suggests that, rather than a progressive course of treatment, early intense induction may reduce complications associated with conventional treatment and improve quality of life. Intensive early therapy with infliximab is known as the "top-down" strategy ( Fig. 1) .
Ethnic differences in the clinical characteristics of CD have been noted. CD is relatively common in developed countries, whereas it is not as common in Asian countries 11) . In addition, recent studies from Far East Asian countries reveal that the prevalence of NOD2 mutations, associated with increased susceptibility to CD in Western populations, is lower than that found in other populations [12] [13] [14] . Therefore, the clinical response to treatment for CD in Asian countries might differ from patients in Western countries.
Step-up strategy Pediatric CD is characterized by frequent relapses, wide disease extent, high prevalence of extraintestinal manifestations, and severe clinical course 15, 16) . Current practice guidelines recommend that most patients with active disease should initially be treated with corticosteroids 17, 18) . Although this approach is usually effective for symptom control, many patients become either resistant to or dependent on these drugs 19) . Long-term exposure to corticosteroids is also associated with complications such as Cushing's syndrome, and therefore, with increased risk of mortality 17, 18, [20] [21] [22] . For this reason, most clinicians initiate treatment with corticosteroid-sparing drugs such as azathioprine, mercaptopurine, or methotrexate once corticosteroid resistance or dependence develops.
Infliximab is an anti-tumor necrosis factor (TNF-α ) monoclonal antibody that was initially used in corticosteroid-dependent and corticosteroid-refractory CD 23) . TNF-α is a pro-inflammatory cytokine that plays a key role in the pathophysiology of a number of inflammatory disorders, including CD. The use of infliximab has been well documented as an effective treatment for moderate to severe CD in children in several studies 24, 25) . Infliximab, as a scheduled treatment, is effective for the induction and maintenance of remission in patients with CD 26, 27) (Fig. 1 ).
Top-down strategy
Early use of infliximab with immunosuppressants, known as topdown therapy, in patients with newly diagnosed CD has resulted in better outcomes in adult patients 28) . An 8-week maintenance treatment schedule with infliximab has been shown to be a cost-effective approach in adult patients with active luminal or fistulizing CD 29) . Such therapy offers the potential for altering the natural history of CD, and is changing treatment paradigms. One possible explanation for the prolonged remission with infliximab treatment is that this medication might help heal mucosal lesions in patients with severe disease as well as those with mild disease 30) . However, the relatively new concept of an early aggressive or topdown treatment approach is not yet widely accepted, especially in pediatric patients, even although some studies have reported that infliximab is more effective in children than in adults 31, 32) (Fig. 1) .
The safety of infliximab
The safety profile of infliximab is an important issue, as its use and indications are rapidly increasing. Infliximab treatment appears to be well tolerated 7) , however, anaphylactic reactions and symptoms caused by immunosuppression, such as upper respiratory tract infections, herpes zoster activation, severe acute bacterial infections, and an increased risk of tuberculosis, have all been described following treatment with infliximab 8, 9, 33) . Pretreatment before infliximab infusion may be helpful in ameliorating these side effects. Little is known about the potential for long-term toxicity in infliximab therapy. After repeated dosing is performed, some patients have human antibodies to chimeric TNF-α antibodies 34) . Repeated administration of chimeric antibodies may be associated with the formation of autoimmune antibodies and a self-limited lupus-like syndrome 35) .The development of lymphoma has been reported as a possible, although rare, long-term complication of anti-TNF therapy in patients with rheumatoid arthritis and CD [36] [37] [38] . Several reports of a possible association between concomitant infliximab and immunomodulator therapy and hepatosplenic T-cell lymphoma (HSTCL) have emerged 37, 38) . However, the mechanism of this possible association remains unclear. Until further evidence emerges, long-term surveillance of patients who have used infliximab in combination with immunomodulators is warranted.
The experience in Samsung Medical Center
We have used infliximab as an induction therapy since 2005. Our patients had a better response to infliximab treatment than compared to conventional therapy. At 8 weeks, remission was achieved in 3 of 11 patients (27.3%) in the step-up group, and in 16 of 18 patients (88.9%) in the top-down group. At 1 year of followup, remission was maintained in 5 of 11 patients (45.5%) and in 15 of 18 patients (83.3%) in the step-up and top-down groups, respectively 39) . At the 1 year follow-up, the relapse rate (23.1%, 3 of 13 patients) in the top-down group was lower than that (61.5%, 8 of 13 patients) in the step-up group (P=0.047). At 2 years followup, the relapse rate (38.5%, 5 of 13 patients) in the top-down group was lower than that (76.9%, 10 of 13 patients) in the step-up group (P=0.047) 40) . The mechanism(s) by which the top-down strategy yields superior results when compared to step-up treatment with regard to remission rates remains unclear. However, it is suggested that the patients in the step-up group had a much longer duration of disease and that they were exposed to more extensive tissue damage. Limbergen et al. 15) reported that infliximab treatment early in the disease course may avoid the irreversible tissue damage often found in later stages of CD. The potential of infliximab to not only induce but also maintain remission is now well studied in adult and pediatric CD cohorts 5, 6, 24) .
Conclusion
The incidence and prevalence of CD in Korea is lower than in developed countries; however, it is rapidly increasing. There is no known cure for CD. Therefore, the goal of treatment is to mitigate inflammation and the associated clinical symptoms. The current treatment guidelines are designed to maintain remission after induction therapy.
According to our experience, early and intensive treatment of pediatric CD patients with infliximab, at initial diagnosis, was more effective for maintaining remission and reducing flares.
